Mon­cef Slaoui re­signs from post-Glax­o­SmithK­line home Medicxi af­ter ha­rass­ment al­le­ga­tions

Mon­cef Slaoui has stepped down from the Eu­ro­pean VC firm Medicxi, ef­fec­tive­ly com­plet­ing his ex­o­dus from ex­ec­u­tive and board po­si­tions af­ter Glax­o­SmithK­line sub­stan­ti­at­ed sex­u­al ha­rass­ment al­le­ga­tions against him ear­li­er this week.

Medicxi had been Slaoui’s main pro­fes­sion­al home in the three years be­fore he took the sci­en­tif­ic lead in the Trump Ad­min­is­tra­tion’s Op­er­a­tion Warp Speed, help­ing com­pa­nies ac­cel­er­ate and scale the first wave of Covid-19 vac­cines. He took a po­si­tion there as a part­ner three months af­ter re­tir­ing as GSK’s R&D chief in 2017, most re­cent­ly help­ing them launch Centes­sa, a well-heeled biotech based off a sim­i­lar mod­el he set up with­in GSK. Slaoui stepped down from Centes­sa on Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER